The CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in the future, also for those with PD-L1-negative disease. Indeed, the true predictive value of PD-L1 as well as tumour mutational burden remains to be determined, as neither biomarker segregates clearly with responsiveness.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response
Journal of Experimental & Clinical Cancer Research Open Access 28 October 2023
-
Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
Journal of Cancer Research and Clinical Oncology Open Access 28 July 2022
-
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
BMC Cancer Open Access 19 January 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 346, 1823–1833 (2016).
Mok, T. S. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. Lancet. 393, 1819–1830 (2019).
Spiegel, D. R. et al. LBA78 — IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo versus platinum-based chemotherapy (chemo) as first-line (1 L) treatment (tx) in PD-L1-selected NSCLC. Ann. Oncol. 30 (suppl. 5), v851–v934 (2019).
Reck, M. et al. OA14.01 KEYNOTE-024 3-year survival update: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer. J. Thorac. Oncol. 14 (Suppl.), S243 (2019).
Nadal, E. et al. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol. Immunother. 68, 341–352 (2019).
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2230 (2018).
West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multi-centre, randomised open-label, phase 3 trial. Lancet Oncol. 20, 924–937 (2019).
Paz-ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
Hellman, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
Hodi, F. S. et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480–1492 (2018).
Brahmer, J. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J. Immunother. Cancer 6, 75 (2018).
Acknowledgements
The authors thank Scott Gettinger, Philip Grover, Mario Sznol and Yang Zhou for their input into the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.S.H. has received honoraria for consultancy from Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Midas Health Analytics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, and Tocagen. R.S.H. has also received research support from AstraZeneca, Eli Lilly and Merck, and is a member of the board of directors (non-executive/ independent) for Junshi Pharmaceuticals. A.C.C. has received honoraria for consultancy or participation on advisory boards from Abbvie Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb and Genentech/Roche. A.C.C. has also received research support from AbbVIe Pharmaceuticals, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Merck.
Supplementary Information
Rights and permissions
About this article
Cite this article
Chiang, A.C., Herbst, R.S. Frontline immunotherapy for NSCLC — the tale of the tail. Nat Rev Clin Oncol 17, 73–74 (2020). https://doi.org/10.1038/s41571-019-0317-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0317-y
This article is cited by
-
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response
Journal of Experimental & Clinical Cancer Research (2023)
-
Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
Journal of Cancer Research and Clinical Oncology (2023)
-
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
BMC Cancer (2022)
-
Is immunotherapy in the future of therapeutic management of sarcomas?
Journal of Translational Medicine (2021)
-
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Nature Reviews Clinical Oncology (2021)